These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 15912621)

  • 1. Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
    Oh DS; Ohning GV; Pisegna JR
    Dig Dis Sci; 2005 May; 50(5):853-7. PubMed ID: 15912621
    [No Abstract]   [Full Text] [Related]  

  • 2. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
    Caro JJ; Salas M; Ward A
    Clin Ther; 2001 Jul; 23(7):998-1017. PubMed ID: 11519776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenomical aspects of gastroesophageal reflux disease].
    Isaev VA
    Vestn Ross Akad Med Nauk; 2005; (6):33-6. PubMed ID: 16022110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rabeprazole: a review of its use in acid-related gastrointestinal disorders.
    Langtry HD; Markham A
    Drugs; 1999 Oct; 58(4):725-42. PubMed ID: 10551440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: efficacy and safety of rabeprazole in treating gastroesophageal reflux disease.
    Lim PW; Goh KL
    J Gastroenterol Hepatol; 2004 Sep; 19 Suppl 3():S61-8. PubMed ID: 15324384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole.
    Adachi K; Hashimoto T; Hamamoto N; Hirakawa K; Niigaki M; Miyake T; Taniura H; Ono M; Kaji T; Suetsugu H; Yagi J; Komazawa Y; Mihara T; Katsube T; Fujishiro H; Shizuku T; Hattori S; Yamamoto S; Kinoshita Y
    J Gastroenterol Hepatol; 2003 Dec; 18(12):1392-8. PubMed ID: 14675268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
    Miner P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rabeprazole sodium.
    Am J Health Syst Pharm; 1999 Nov; 56(22):2300. PubMed ID: 10582820
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of rabeprazole in gastroesophageal reflux disease: report of a multicenter study.
    Kar P; Chandrashekar N; Devi S; Bhatia SJ; Alvares JF; Taneja A; Towar A
    Indian J Gastroenterol; 2003; 22(4):153. PubMed ID: 12962446
    [No Abstract]   [Full Text] [Related]  

  • 14. Retreatment of H. pylori with dual therapy using high doses of rabeprazole or lansoprazole can be effective.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1175-6. PubMed ID: 14653841
    [No Abstract]   [Full Text] [Related]  

  • 15. Rabeprazole is latest entrant in proton-pump-inhibitor class.
    Miller JL
    Am J Health Syst Pharm; 1999 Oct; 56(19):1910. PubMed ID: 10554904
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
    Maev IV; Balashova NN; Busarova GA
    Klin Med (Mosk); 2003; 81(9):54-9. PubMed ID: 14598594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
    Thomson AB
    Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
    Sloan S
    Am J Gastroenterol; 2003 Mar; 98(3 Suppl):S49-55. PubMed ID: 12644031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of proton pump inhibitors.
    Der G
    Gastroenterol Nurs; 2003; 26(5):182-90. PubMed ID: 14603076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.